ライフサイエンスコーパス: failure

1 ilities of end points (e.g., death or system failure).

2 cute respiratory failure, and cardiovascular failure).

3 s (or prior, in the event of early treatment failure).

4 s on human spermatogenesis and spermatogenic failure.

5 t-tubule organization and accelerated heart failure.

6 ion, stroke, or hospital admission for heart failure.

7 er time, these chronic loads can cause heart failure.

8 ities, including pericardial edema and heart failure.

9 ther improve outcomes in patients with heart failure.

10 1 and 2014 to determine risk factors for FMT failure.

11 spiratory and autonomic dysfunction in heart failure.

12 included death and death-censored allograft failure.

13 sed grafts to treat patients with intestinal failure.

14 pertrophic cardiomyopathy and advanced heart failure.

15 e CpGs novel epigenetic biomarkers for heart failure.

16 GATA3 function could lead to early pregnancy failure.

17 ane oxygenation for severe acute respiratory failure.

18 rdial infarction, ischemic stroke, and heart failure.

19 ABMR) is a leading cause of kidney allograft failure.

20 frequently associated with multisystem organ failure.

21 prerenal and intrinsic acute renal allograft failure.

22 in system inhibitors for patients with heart failure.

23 ty remains unresolved in patients with heart failure.

24 yopathy (DCM) is an important cause of heart failure.

25 ions, including stroke, eclampsia, and organ failure.

26 singly used in the management of respiratory failure.

27 n the kidney, it predicts the onset of renal failure.

28 that regulates FGF23 expression during renal failure.

29 rtension, obstructive sleep apnoea and heart failure.

30 ocandin therapy altered the risk of clinical failure.

31 iretroviral therapy and to prevent virologic failure.

32 rget in a number of diseases including heart failure.

33 it is the second most common cause of liver failure.

34 on cause of childhood hypertension and renal failure.

35 n unselected patients with acute respiratory failure.

36 including cardiovascular mortality and heart failure.

37 ed, but suggested an increased risk of renal failure.

38 ses, including cardiac hypertrophy and heart failure.

39 ations were investigated in the AL treatment failures.

40 nearly all (70 [89%] of 79) XR-NTX induction failures.

41 ents (CVEs) including 281 (23.8%) with heart failure, 109 (9.2%) with atrial fibrillation, 89 (8%) wi

42 ; one related to treatment), and respiratory failure (14 [6%]).

43 iting photosynthesis and promoting hydraulic failure, (2) increases carbon costs during periods of ca

44 reatment), pneumonia (27 [11%]), acute renal failure (25 [10%]; five related to treatment), pyrexia (

45 ounts in the highest 50% had a risk of graft failure 3.59 times as high (95% confidence interval, 1.1

46 ough week 24 were anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4 [2%]), and pneumonia (4 [2%

47 d cBIN1 level decreased in humans with heart failure, a condition with reduced cardiac muscle cBIN1,

48 Acute-on-chronic liver failure (ACLF) in cirrhosis is an increasingly recognize

49 , especially in patients with multiple organ failure (acute-on-chronic liver failure grade 2-3).

50 71, and 1 125 231 hospitalizations for heart failure, acute myocardial infarction, and pneumonia, res

51 ients discharged from a previous acute heart failure admission.

52 ith dihydroartemisinin-piperaquine treatment failure after adjusting for the presence of amplified pl

53 ged as the most important cause of treatment failure after allogeneic hematopoietic stem cell transpl

54 composite outcome of incident ASCVD or heart failure after further stratifying by CAC (0, 1-100, or >

55 ssociated with worse outcomes in acute heart failure (AHF).

56 n and mortality in patients with acute liver failure (ALF).

57 cohort, the primary outcomes were treatment failure and adverse events 14 days after diagnosis.

58 if (PAM) of the target sequence cause immune failure and allow viral escape.

59 ng DJ-1 were associated with increased organ failure and death.

60 nsumptive coagulopathy, and subsequent organ failure and death.

61 plex (TCC) that together contribute to organ failure and death.

62 (SPI) were systemic and led to multiorganic failure and death.

63 iovascular events may be enhanced when heart failure and glucose intolerance coexist and may be atten

64 n of resident OPCs to overcome remyelination failure and halt disease progression.

65 associated with increased risk of technical failure and poor pancreas allograft outcomes.

66 in a pig model with features of human heart failure and preserved ejection fraction with sternum int

67 treatment of subsets of patients with heart failure and pulmonary hypertension.

68 athophysiology of aortic stenosis with heart failure and reduced ejection fraction and summarizes the

69 y patients' characteristics that may predict failure and removal of the Linx sphincter augmentation d

70 ated significantly later with comorbid heart failure and renal failure, with absence of fever or hypo

71 inary sepsis in one patient, and acute renal failure and respiratory failure in one patient) were sus

72 brane oxygenation in adults with respiratory failure and sepsis is steadily increasing, but the knowl

73 isk of cardiovascular disease, stroke, heart failure, and atrial fibrillation.

74 to treatment (pneumonitis, acute respiratory failure, and cardiovascular failure).

75 to development of atrial fibrillation, heart failure, and death.

76 iliary strictures as a risk factor for graft failure, and does not validate other risk factors for IC

77 Older age, congestive heart failure, and greater left ventricular dilation at diagno

78 r nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome

79 for both groups older age, congestive heart failure, and increased left ventricular end-systolic dim

80 bling substantial catch-up from early growth failure, and leveraging improved learning from concomita

81 Incident CVD included CHD, stroke, heart failure, and peripheral arterial disease.

82 ary insufficiency, index admission for heart failure, and stroke.

83 lass III or IV, previous admission for heart failure, and valve disease) and non-cardiac variables (b

84 roup [coronary artery disease and multiorgan failure] and three in the trastuzumab emtansine group [m

85 05 [1.02-1.09]; p = 0.003), Sequential Organ Failure Assessment (relative risk = 1.09 [1.00-1.18]; p

86 ement in the cardiovascular Sequential Organ Failure Assessment (SOFA) score (scores range from 0 to

87 nts in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score, introduced quick SOFA (

88 The sensitivity of quick Sequential Organ Failure Assessment for predicting critical care interven

89 Accuracy of the quick Sepsis-related Organ Failure Assessment score, Sepsis-related Organ Failure A

90 ilure Assessment score, Sepsis-related Organ Failure Assessment score, systemic inflammatory response

91 Response Syndrome and quick Sequential Organ Failure Assessment scores were calculated, and their rel

92 d with a higher risk of early pancreas graft failure at 3 months.

93 l samples from patients with end-stage heart failure at time of transplant, with or without diabetes

94 yocardial infarction, new or worsening heart failure, atrial fibrillation, stroke, deep venous thromb

95 cant difference in the rate of target-vessel failure between the patients who received a bioresorbabl

96 Outcome measures were implant and FPD failures, biologic and prosthetic complications, and mar

97 heat treatment, is known to cause disastrous failure, but its mechanism is still not completely clear

98 unction (CVpef) is associated with treatment failure, but the pattern of change in self-similarity le

99 as associated with all-cause death and heart failure, but the result was not significant (P=0.051).

100 stimulation have been reported in left heart failure, but whether it would be beneficial for pulmonar

101 data and to characterize data communication failures by type.

102 virus (HIV)-infected patients with end organ failure can safely receive an organ transplant from an H

103 valuation of congenital heart disease, heart failure, cardiac masses, pericardial disease, and corona

104 ploy in harsh reservoir conditions and where failures cause material aggregation and sticking to rock

105 MDS/MPN) and 3 patients (1.1%) developed BM failure characterized by cytopenia and BM aplasia.

106 uation of Sedation Titration for Respiratory Failure clinical trial.

107 tegies for Management of Patients with Heart failure) clinical cohort study, 496 patients with acute

108 llitus) are characteristic features of heart failure; conversely, neurohormonal systems activated in

109 l cure, defined as absence of these clinical failure criteria at follow-up visits: fever; increase in

110 plying the recently introduced Chronic Liver Failure-criteria.

111 Cumulative incidences of graft failure, cytomegalovirus, and/or adenoviral infections a

112 RATIONALE: In patients with chronic heart failure, daytime oscillatory breathing at rest is associ

113 higher rate of hospital admission for heart failure decompensation in follow-up (HR, 1.66; 95% CI, 1

114 Treatment failure developed in 102 of the 801 patients (12.7%).

115 vasive telemonitoring in patients with heart failure does not reduce mortality or hospitalizations, l

116 rapy for toxic ingestion or idiopathic liver failure (DT) in a level 1 trauma center and large transp

117 ciated with an increased risk of virological failure during treatment with NNRTI-containing regimens.

118 30% to 40% of patients with congestive heart failure eligible for cardiac resynchronization therapy (

119 There were 248 treatment-failure events in the combination group as compared with

120 s the only available option after first-line failure for the majority of individuals living with huma

121 a 3-month and a 6-month cohort of "treatment failures" from both CATT and DRCR.net studies.

122 ltiple organ failure (acute-on-chronic liver failure grade 2-3).

123 tal quartile of ICU use for congestive heart failure had a sensitivity of 50-60% and specificity of 7

124 function may contribute to those therapeutic failures has not been clarified.

125 Approximately half of patients with heart failure have preserved ejection fraction.

126 ciated with increased hazards of virological failure (hazard ratio [HR] 2.6, 95% CI 2.5-2.8; p<0.0001

127 ycline chemotherapy is associated with heart failure (HF) among survivors of non-Hodgkin lymphoma (NH

128 Although heart failure (HF) disproportionately affects older adults, li

129 Patients with heart failure (HF) have high mortality and mobility.

130 arations isolated from human donor and heart failure (HF) left ventricle.

131 perfused hearts from control (CTL) and heart failure (HF) mice (HF induced by transaortic constrictio

132 ABSTRACT: Heart failure (HF) patients with preserved ejection fraction (

133 assess the impact of interventions on heart failure (HF) patients' functional status.

134 ole of ischemic heart disease (IHD) in heart failure (HF) with reduced ejection fraction (HFrEF; EF <

135 ospitalization, thromboembolic events, heart failure (HF), and AF progression.

136 Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely u

137 ers increase survival in patients with heart failure (HF), the mechanisms behind this protection are

138 ively studied in patients with chronic heart failure (HF), with only limited success.

139 therapeutic approach for treatment of heart failure (HF).

140 independently associated with risk of heart failure (HF).

141 e cardiac fibrosis (CF) in nonischemic heart failure (HF).

142 central tenets of patient education in heart failure (HF).

143 CI: 0.07 to 0.75), total mortality or heart failure hospitalization (aHR: 0.32; 95% CI: 0.12 to 0.82

144 point or day-30 all-cause mortality or heart failure hospitalization rate differed between the 2 grou

145 range) showed strong associations with heart failure (HR: 2.04; 95% confidence interval [CI]: 1.82 to

146 is was associated with decreased risk of IRA failure (HR=0.6, 95% CI 0.4-0.97).

147 er limb ischemia - diabetes, end-stage renal failure, hyperparathyroidism, or even symptoms of left u

148 e mortality at 1 year in patients with heart failure in Africa, China, India, the Middle East, southe

149 cardiac hypertrophy and progression to heart failure in both vitamin D deficient and normal mice with

150 highly effective in reducing 90% of vaccine failure in children.

151 become a surrogate for treatment success or failure in common lymphoma subtypes.

152 es following a first-time diagnosis of heart failure in Denmark between 1995 and 2012.

153 ions is thought to contribute to therapeutic failure in invasive pulmonary aspergillosis (IPA).

154 ent, and acute renal failure and respiratory failure in one patient) were suspected to be related to

155 be a major contributing factor in treatment failure in patients with atopic dermatitis, yet it has b

156 n plays an important role in treating kidney failure in patients with end-stage liver disease.

157 entification and stratification of induction failure in patients with pediatric acute lymphoblastic l

158 ting oligodendrocyte death and remyelination failure in the cuprizone model (male mice).

159 likelihood of retransplantation after graft failure in those aged 18 to 24 years.

160 beta-Cell failure in type 2 diabetes (T2D) was recently proposed t

161 The risk of graft failure in young kidney transplant recipients has been f

162 s a key reason for the frequent regeneration failures in humans, the transcriptional mechanisms that

163 The failures in the gene regulatory network that lead to can

164 Thus, failures in the secretion of nonbulky proteins, ER stres

165 expression, coinciding with secondary energy failure, in lesioned mice compared to controls.

166 From 2002 to 2014, heart failure incidence (standardised by age and sex) decrease

167 4.1 years, surgery patients had lower heart failure incidence than lifestyle modification patients (

168 3 associated with simeprevir or paritaprevir failure include R155K and D168E/V.

169 h short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight absorption and

170 on drug recently approved for treating heart failure, inhibits stretch-induced hypertrophy, and predi

171 Here, in the International Congestive Heart Failure (INTER-CHF) study, we aimed to measure mortality

172 Specifically, the risk of developing heart failure is higher in patients with diabetes or obesity,

173 e in self-similarity leading up to treatment failure is variable across individuals.

174 Liver failure (LF) is associated with prolonged hospital stay,

175 he cause of nutritional dyshomeostasis (oral failure, malabsorption, or both), and to quantify the ef

176 e to expand the use of pressure-guided heart failure management.

177 ad persisting symptoms compatible with heart failure (median of 13 [range 0-76] in the Minnesota Livi

178 cotherapies for African Americans (eg, heart failure medications), disease management is less effecti

179 h-risk HPV post-treatment predicts treatment failure more accurately than margin status.

180 endpoint were age, anemia, congestive heart failure, multivessel disease, number of stents implanted

181 has been detected in cardiomyopathies, heart failure, myocardial ischaemia, and hypertrophy.

182 Conclusion In the absence of known renal failure, neonates receiving standard inpatient care do n

183 ly, neurohormonal systems activated in heart failure (norepinephrine, angiotensin II, aldosterone, an

184 Noninvasive ventilation failure occurred in 15.2%, and in-hospital mortality was

185 Outcomes were evaluable in 444 failure occurred in 187 (42.1%; 95% confidence interval,

186 Clinical failure occurred in 7 patients (20%) treated with an ech

187 as associated with a significant risk of FMT failure (odds ratio, 0.15; 95% confidence interval, .007

188 an adjusted hazard ratio (aHR) for treatment failure of 20.4 (95% CI 9.1-45.5, p<0.0001).

189 d factors associated with the indication and failure of a medication step-down treatment.

190 k of a known correlate of protection and the failure of a neutralizing antibody to correlate with pro

191 al health community can judge the success or failure of a Trump presidency, based on a selection of t

192 The failure of cells lacking adenylyl cyclase (cyr1Delta) to

193 Failure of conventional imaging-using predominately sing

194 -Saharan Africa in patients with virological failure of first-line combination antiretroviral therapy

195 cell fusion assays show a strain-independent failure of fusion pore enlargement among H2 (A/Japan/305

196 e asthma with respiratory muscle fatigue and failure of medical treatment.

197 was defined as symptomatic congestive heart failure of New York Heart Association class III or IV, c

198 Failure of OFOQ to detect HIV-1 infection was frequent a

199 Failure of phagocytosis could be induced experimentally

200 e the efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent impl

201 that dwell time was the only risk factor for failure of standard retrieval technique (odds ratio, 1.0

202 bility criteria included measurable disease, failure of standard therapy, and Eastern Cooperative Onc

203 reactivation which is likely linked with the failure of the monocytes to differentiate to a DC phenot

204 rative disease, characterised by progressive failure of the neuromuscular system.

205 Failure of this closure process leads to open spina bifi

206 Failure of this migration during neuroepithelium formati

207 Failure of this protective mechanism may contribute to d

208 The successes and failures of biologics in clinical trials have facilitate

209 collaboration who had locally defined viral failure on first-line therapy with tenofovir plus a cyto

210 ent-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all in the 10-d

211 ) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk di

212 The ability to predict graft failure or primary nonfunction at liver transplant decis

213 No postoperative fractures, implant failures or loosening problems occurred; mean Musculoske

214 robability of corneal transplantation, graft failure, or both were calculated based on data from publ

215 k of dying from myocardial infarction, heart failure, or stroke, respectively, than members of the ge

216 ocardial infarction, stent thrombosis, heart failure, or target vessel revascularization.

217 gned to placebo were classified as treatment failures (p=0.0974).

218 ammation is the primary determinant in heart failure pathology post-MI.

219 to Improve Outcomes in NYHA Class III Heart Failure Patients [CHAMPION]; NCT00531661).

220 Forty consecutive heart failure patients underwent planar acquisition 4 h after

221 mprovement of patient health status in heart failure patients with low self-reported hrQoL, but not i

222 with left bundle branch block (LBBB), heart failure patients with narrow QRS and nonspecific intrave

223 k Heart Association class IV (NYHA IV) heart failure patients.

224 -scale technology needed to treat intestinal failure patients.There is a need for humanised grafts to

225 with respect to rescuing the cellular heart failure phenotype.

226 but no RASs were associated with ledipasvir failure, pointing to a limited efficacy of ledipasvir in

227 entary capabilities if modes of internetwork failure propagation are constrained.

228 nge 0-76] in the Minnesota Living with Heart Failure Questionnaire) and cardiac limitation on exercis

229 ical and biologic complications, and implant failure rate associated with use of DAs and PAs.

230 t loss once DSA was detected, reaching a 28% failure rate within 2 years.

231 suggested that this regimen may lead to high failure rates in coinfected patients.

232 ded by partner drug resistance, causing high failure rates of artemisinin combination therapies in so

233 use mortality among patients with transplant failure reentering HD.

234 or interstitial nephritis, as cause of renal failure, represented the only predictive factor for MGUS

235 Thirteen of these 23 (56.5%) virologic failures resuppressed after a median of 8.0 months (inte

236 Although heart failure risk models perform reasonably well at the popul

237 s of all ages had significantly higher graft failure risks than males (adjusted hazard ratios 0-14 ye

238 ssociated with a 58% increased risk of heart failure (RR 1.58; 95% CI, 1.46 to 1.72) and a 40% increa

239 characterized by acute decompensation, organ failure(s) and high short-term mortality.

240 sing various real-world node-attack and node-failure scenarios.

241 kg/m(2)), worse Minnesota Living With Heart Failure score (48 versus 40), higher median N-terminal p

242 In human heart failure, Ser199 (equivalent to Ser200 in mouse) of cTnI

243 cally, at times be the source of performance failures.SIGNIFICANCE STATEMENT The performance-monitori

244 of patients of black race, those with heart failure signs at admission, and bleeding complications i

245 ise from interventional cardiologists, heart failure specialists, cardiac surgeons, and cardiac anest

246 , nonfatal myocardial infarction [MI], heart failure, stroke, transient ischemic attack, peripheral a

247 These comprised 105 vaccine failure subjects who received 3 doses of HBV vaccine in

248 and Ea were associated with worsening heart failure symptoms at 1 year.

249 l help identify, and eventually correct, the failures that lead to the deterioration of this importan

250 When there are no internal failures the model is equivalent to a bipartite system,

251 The agency's failure to adequately account for the risks of perchlora

252 Hemispatial Neglect (HN) is a failure to allocate attention to a region of space oppos

253 ted with outcomes of remission and treatment failure to CBT and antidepressant medication and survive

254 f CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality.

255 n via massive vesicle release and subsequent failure to endocytose lost vesicles.

256 accumulated bystander mutations indicating a failure to express their products at the cell surface in

257 of Hsp104 function in yeast cells leads to a failure to generate new propagons, the molecular entitie

258 The failure to identify mutation carriers among probands rep

259 Failure to improve clinical outcome occurred even though

260 Trial ineligibility was mostly due to failure to meet inclusion criteria (87% of screening ass

261 ts effectiveness is frequently undermined by failure to obtain follow-up colonoscopy after positive t

262 Failure to obtain informed consent and associated medica

263 .70 vs 2.77 instances per hour, P = .03) and failure to progress (mean, 1.20 vs 0.13 instances per ho

264 cal dynein inhibition in zebrafish result in failure to properly distribute mbp mRNA in oligodendrocy

265 EGFR-TKI use, EGFR-TKI resistance mutation, failure to receive EGFR-TKI after WBRT/SRS, or insuffici

266 Failure to reduce the dose in patients with severe kidne

267 of repair cells and regeneration tracks, and failure to sustain expression of repair cell markers, in

268 l heart disease, skeletal abnormalities, and failure to thrive.

269 The failure to undergo remyelination is a critical impedimen

270 e S187A mutant died in the first week due to failure to undergo the peroxisome proliferator-activated

271 sis genes prominently in RP-mediated DBA and failure to upregulate components of the translational ap

272 In a multivariate analysis, failure to use an oral vancomycin taper preceding FMT wa

273 The failure-to-rescue rate is a useful metric for evaluating

274 or associations with major complications and failure-to-rescue.

275 rubinemia and/or Encephalopathy and/or Renal Failure trial by applying the recently introduced Chroni

276 ar Improvements With MV-ASV Therapy in Heart Failure) trial investigated whether minute ventilation (

277 t on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients with chro

278 tegies for Management of Patients with Heart failure [TRIUMPH]; NTR1893).

279 components that are vulnerable to cascading failures under any out of multiple conditions.

280 An index that is derived to predict graft failure using donor and recipient factors, based on loca

281 Local treatment failure was a relatively infrequent event after I-125 br

282 bably due to immunosenescence, because heart failure was associated with increased senescent CD4+ T c

283 Technical failure was defined as no pixel value with a confidence

284 The hazard of graft failure was estimated at each current age using a 2-stag

285 Time to treatment failure was longer with bevacizumab than with IFN (HR, 0

286 In the latter patient, acute renal failure was not suspected to be related to everolimus tr

287 of death, transplant, or admission for heart failure was reached in 88 patients.

288 ted to everolimus treatment, but respiratory failure was suspected to be related.

289 f 62 days from debridement; patients without failure were followed up for a median of 802 days.

290 The most common reasons for failure were SUV outside specifications, incomplete subm

291 A demonstrated elevated risks of early graft failure, whereas those with de novo DSA experienced acce

292 therapy (CRRT) benefits patients with renal failure who are too hemodynamically unstable for intermi

293 in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET of CH

294 ODS AND We randomized 12 subjects with heart failure with preserved ejection fraction to oral KNO3 (n

295 In heart failure with preserved ejection fraction, patients with

296 irst study to evaluate elamipretide in heart failure with reduced ejection fraction and demonstrates

297 g all-cause mortality in patients with heart failure with reduced ejection fraction.

298 under investigation for patients with heart failure with reduced left ventricular ejection fraction.

299 treating malaria patients with uncomplicated failures with the same ACT used for the primary episode,

300 later with comorbid heart failure and renal failure, with absence of fever or hypotension, and in in